Compounds which activate nicotinic acetylcholine receptors of the α7 receptor subtype (nAChR α7) have received considerable attention because of their potential to treat cognitive symptoms in patients with schizophrenia or Alzheimer’s disease (AD) [1, 2]. Here, CHRNA7 is linked to early-onset autosomal dominant Alzheimer disease.